Inhaled Zolmitriptan for Acute Treatment of Migraine

CVT-427 is an investigational agent under development for the acute treatment of migraines – painful headaches that may be accompanied by nausea, vomiting or sensitivity to light. An estimated 36 million people in the US, and over 40 million people in Europe, suffer from migraines.

Using our proprietary ARCUS® technology, CVT-427 is a novel inhaled formulation of zolmitriptan. Zolmitriptan belongs to a class of drugs known as triptans. Triptans, which are most commonly taken orally, are a leading therapy for acute treatment of migraines. There are currently no approved inhaled migraine therapies.

A majority of migraine sufferers say rapid pain relief is the most important factor influencing their medication preference. Oral triptans can be associated with slow onset of action, as the medicine is absorbed through the gastrointestinal (digestive) tract before reaching the brain. Another consideration in treatment of acute migraine is nausea. It is estimated that almost 90% of people with migraines experience nausea, making swallowing an oral therapy unpleasant and potentially difficult to keep down.

Inhaled treatments, such as those that utilize our ARCUS technology, enter the body through the lungs and reach the brain shortly thereafter, bypassing the digestive system. Clinical trials will evaluate the effect of CVT-427 following administration, in addition to tolerability and safety measures.

We presented data from Phase 1 clinical trial of CVT-427 at the 58th Annual Scientific Meeting of the American Headache Society in June, 2016.